Antitum of Mechanism of Hybrid Liposomes and Clinical Application
Antitum of Mechanism of Hybrid Liposomes and Clinical Application
批准号:
12555232
负责人:
UEOKA Ryuichi
金额:
$6.4万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1. Antitumor Mechanism of Hybrid LiposomesWe examined mitochondrial pathway for apoptosis induced by hybrid liposomes. Mitochondrial membrane potential was decreased by adding hybrid liposomes, suggesting that hybrid liposomes should induce apoptosis through mitochondria. Release of cytochrome c and activation of caspase-9 were observed using western blotting analysis. Concentration dependence of caspase-9 inhibitor on the apoptotic DNA rates was also obtained. These results suggest that hybrid liposomes should induce apoptosis through mitochondria and activation of caspase-9.2. Inhibitory Effects of Three-Component Hybrid Liposomes Including Sugar SurfactantsWe successfully produced sugar-type micellar surfactants, lactonoalkylamide (LacCn), for the first time. Spherical vesicles, three-component hybrid liposomes, were obtained after sonication of mixture of L-α-dimyristoylphosphtidylcholine (DMPC), Tween 20 and LacCn (DMPC : Tween 20 : LacCn = 65 : 7 : 28). It is noteworthy that high … More inhibitory effects of the three-component hybrid liposomes composed of DMPC, Tween 20, and LacCn (DMPC : Tween 20 : LacCn = 65 : 7 : 28) on the growth ofglioma (U251) and lung adenocarcinoma (RERF-LC-OK) cells were attained in vitro without any drug, although no significant inhibitory effects of any individual component (DMPC, Tween 20, LacCn) or the two-component hybrid liposomes of DMPC and Tween 20 on the growth of tumor cells examined were obtained.3.Clinical Application of Hybrid LiposomesPatients with lymphoma were selected for the clinical application of hybrid liposomes composed of DMPC and C_<12>(EO)_<23> without any drug after passing the committee of bioethics. The hybrid liposomes were administered intravenously every day. There were not abnormal findings on routine blood test and hematochemistry. Prolonged survival was attained in patient with lymphoma after the intravenous injection of hybrid liposomes without any side effect and the remarkable reduction of neoplasm (solid tumor) was obtained after the local administration of hybrid liposomes. Such a successful clinical application of hybrid liposomes without drugs was for the first time in the world. Less
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Yoko Matsumoto: "Bioorganic & Medicinal Chemistry Letters"Highly Specific Inhibitory Effect of Three-Component Hybrid Liposomes Including Sugar Surfactants on the Growth of Glioma Cells. 10巻. 2617-2619 (2000)
Yoko Matsumoto:“生物有机与药物化学快报”包括糖表面活性剂的三组分混合脂质体对神经胶质瘤细胞生长的高度特异性抑制作用。第 10 卷。2617-2619 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ryuichi Ueoka: "Chemical & Pharmaceutical Bulletin"Remarkably Enhanced inhibitory Effects of Three-Component Hybrid Liposomes Including Sugar Surfactants on the Growth of Lung Carcinoma Cells. 50巻・4号. 563-565 (2002)
Ryuichi Ueoka:《化学与制药通报》显着增强含糖表面活性剂的三组分混合脂质体对肺癌细胞生长的抑制作用。第 50 卷,第 4 期。563-565 (2002)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ryuichi Ueoka: "Marked Therapeutic Effect of Dimyristoylphosphatidylcholine Liposomes on Carcinoma Mice Model in Vivo"Biological & Pharmaceutical Bulletin. 23. 1262-1263 (2000)
Ryuichi Ueoka:“二肉豆蔻酰磷脂酰胆碱脂质体对体内癌小鼠模型的显着治疗作用”生物学
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ryuichi Ueoka: "Marked Therapeutic Effect of Dimyristoylphosphatidylcholine Liposomes on Carcinoma Mice Model in Vivo"Biological & Pharmaceutical Bulletin. 23巻・10号. 1262-1263 (2000)
Ryuichi Ueoka:“二肉豆蔻酰磷脂酰胆碱脂质体对体内癌症小鼠模型的显着治疗效果”《生物与药物通报》第 23 卷,第 10 期。1262-1263 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
松本陽子: "制がん性複合脂質膜のアポトーシス誘導"化学工学会. (2001)
Yoko Matsumoto:“抗癌复合脂质膜中细胞凋亡的诱导”日本化学工程师学会(2001)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 14 条
Medical technological study of nano chemotherapy using hybrid liposomes for the refractory disease
-
批准号:25289299
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2013
-
负责人:UEOKA Ryuichi
-
依托单位:
Basic and applied study on AIDS-therapy using hybrid liposomes
-
批准号:24656509
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.58万
-
财政年份:2012
-
负责人:UEOKA Ryuichi
-
依托单位:
Development of Nanotherapy System for Intractable Disease with Hybrid Liposomes-Cancer therapy with hybrid liposomes-
-
批准号:20360377
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.4万
-
财政年份:2008
-
负责人:UEOKA Ryuichi
-
依托单位:
Chemotherapy with hybrid liposomes and application to drug delivery system with hybrid liposomes
-
批准号:17360403
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$10.48万
-
财政年份:2005
-
负责人:UEOKA Ryuichi
-
依托单位:
Explanation of the Anticancer Mechanism and Clinical Chemotherapy for Hybrid Liposomes
-
批准号:14350439
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.22万
-
财政年份:2002
-
负责人:UEOKA Ryuichi
-
依托单位:
Functional Molecular Assemblies Coupled to Steric Control with High Enantioselectivity
-
批准号:07650968
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.34万
-
财政年份:1995
-
负责人:UEOKA Ryuichi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
基于Notch-1介导miR-200家族调控上皮间质转化对绒癌耐药机制的研究
-
批准号:81972428
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:安瑞芳
-
依托单位:
地塞米松诱导的人卵巢癌对化疗药物耐受及其机制的研究
-
批准号:81172471
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2011
-
负责人:陈玉霞
-
依托单位:
维生素B3促进化疗导致粒细胞减少症的中性粒细胞生成功能及作用机制研究
-
批准号:81060045
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:蓝丹
-
依托单位:
番荔枝内酯抗肿瘤作用及调节肿瘤耐药分子调控网络研究
-
批准号:30973854
-
项目类别:面上项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:欧阳学农
-
依托单位:
应用蛋白敲除技术降解ErbB家族的抗乳腺癌作用及其机制研究
-
批准号:30901754
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:李慧
-
依托单位:
卵巢癌肿瘤干细胞特异性microRNA分子靶点调控的研究
-
批准号:30873011
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2008
-
负责人:沈铿
-
依托单位:
巨噬细胞诱导的大肠癌靶向治疗实验研究
-
批准号:30471998
-
项目类别:面上项目
-
资助金额:20.0万元
-
批准年份:2004
-
负责人:张继民
-
依托单位: